VORANIGO (R) was approved by Health Canada in August 2024 for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation in adults and pediatric patients aged ...
If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or ...
Recently published chondrosarcoma Market Insights report includes a comprehensive understanding of current treatment practices, ...
A woman in her late 20s presented with a 5-year history of progressive fatigue and generalised weakness. Examination revealed signs of premature ageing, anaemia, neuropathy and hepatosplenomegaly.
2d
Coding for a cure: Sewickley Academy student’s research reveals key differences in genetic mutations
Being invited to present research at an international academic conference is an honor for any seasoned professional. But for ...
While the genes involved can differ, this example illustrates how most cancers arise. Accumulated DNA mutations, acquired either over time (ageing naturally leads to some DNA mistakes) or from ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...
Dive into the world of Solo Leveling and learn about Jinwoo's Shadow Army. Understand the importance and power of each grade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results